MHRA Issues Field Safety Notice for Nova StatStrip® Ketone Test Strips
The MHRA has issued a Field Safety Notice for Nova Biomedical's StatStrip® Ketone Test Strips, requiring immediate action from distributors and users. This impacts diagnostic device procurement and inventory management for brands utilising these strips.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 09 October 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Field Safety Notice (FSN) for Nova Biomedical’s Nova StatStrip® Ketone Test Strips. Issued on 9 October 2026, the notice, identified by MHRA reference 41092838, indicates a critical safety concern requiring immediate attention from all entities involved in the distribution and use of these diagnostic devices. While specific details of the defect are not disclosed in the notice, Field Safety Notices typically relate to product performance issues, potential inaccuracies, or risks to user safety, necessitating corrective actions.
For supplement brands whose product efficacy or usage protocols rely on accurate ketone monitoring, this FSN mandates a thorough review of current practices. Procurement teams must ascertain if their supply chains include the affected Nova Biomedical strips and initiate quarantine procedures for any implicated stock. Failure to act swiftly could result in the distribution of potentially unreliable diagnostic tools, undermining brand credibility and exposing companies to liability risks. Quality control departments must update their supplier vetting processes to account for such advisories.
Distributors holding inventory of these ketone test strips must immediately comply with Nova Biomedical’s instructions, which typically include identification, segregation, and return or disposal of affected lots. The financial implications include potential write-offs of inventory, increased administrative costs for recall management, and the urgent need to secure alternative, compliant testing supplies. This disruption could impact product launches or ongoing monitoring programmes that integrate ketone level assessment.
What this means for United Kingdom
UK manufacturers and brand owners must conduct an urgent internal audit to confirm exposure to the affected Nova StatStrip® Ketone Test Strips. Procurement departments should immediately engage with suppliers to verify batch numbers and ensure compliance with the FSN directives by 16 October 2026 to mitigate risk. Non-compliance could lead to MHRA enforcement actions, including product removal from market and significant reputational damage. Brands that integrate ketone monitoring into their product propositions face immediate reformulation or protocol adjustments, creating an opportunity for competitors with validated alternative testing solutions to gain market share.
The incident underscores the importance of robust post-market surveillance for all device components within the supplement ecosystem. Companies must ensure their quality management systems can rapidly respond to and implement Field Safety Notices, protecting both consumers and brand integrity. Proactive engagement with regulatory updates from bodies like the MHRA is paramount for maintaining market access and consumer trust.
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.